PRX019 is an investigational potential disease-modifying treatment candidate for neurodegenerative diseases under Prothena and Bristol Myers Squibb collaboration. The U.S. FDA cleared its IND in December 2023. Development entered first-in-human Phase 1 planning in 2024.
Prothena reported Q4 and full year 2025 financial results with $308.4 million in cash as partners Roche and Novo Nordisk initiated Phase 3 trials for prasinezumab and coramitug, both expected to complete in 2029.
Prothena reported Q4 2025 adjusted loss of 45 cents per share, meeting estimates, while ending the year with $308.4 million in cash. Roche and Novo Nordisk advanced partnered programs prasinezumab and coramitug into Phase III trials.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06699680 |
Phase 1 Study of PRX019 in Healthy Adult Volunteers |
COMPLETED | PHASE1 |
